Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but "difficult-to-drug" target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. Browse Full Report With TOC @ http://www.researchmoz.us/rorgamma-modulators-2016-a-comparative-analysis-of-the-landscape-of-rorgamma-antagonists-and-agonists-report.html
http://www.researchmoz.us/rorgamma-modulators-2016-a-comparative-analysis-of-the-landscape-of-rorgamma-antagonists-and-agonists-report.html
No comments:
Post a Comment